Lixte Biotechnology Holdings, Inc. Signs Amendment to Development Collaboration Agreement

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) recently announced the signing of an amendment to its Development Collaboration Agreement. The company had initially entered into this agreement on October 8, 2021, with the Netherlands Cancer Institute, Amsterdam (NKI), and Oncode Institute, Utrecht. The collaboration aimed to identify potential drugs to combine with LB-100 and LB-100 analogues for treating various cancers and understand the underlying molecular mechanisms of these combinations.

The newly signed amendment, referred to as Amendment 3, entails a temporary pause in ongoing study activities and payments under the Collaboration Agreement until the commencement of a Phase 1b clinical trial. This trial involves combining LB-100 with a WEE1 inhibitor for metastatic colorectal cancer patients. The collaboration will resume upon dosing the first patient in this trial, with the termination date revised to one year from the dosing date of the first patient.

Amendment 3 also allows the parties to analyze translational data from patient samples in clinical trials at NKI. This amendment includes a reduced annual budget of €100,000, invoiced quarterly, for a year following the Effective Date, compared to the initial budget of €250,000. The details provided are subject to the full text of Amendment 3, which is available as Exhibit 10.1 in the filing.

In addition to this development, Lixte Biotechnology Holdings, Inc. reported that their Common Stock (LIXT) and Warrant to Purchase Common Stock (LIXTW) are registered on The Nasdaq Stock Market LLC.

Investors interested in more specifics can refer to the full 8-K filing which includes details of the Development Collaboration Agreement, Amendment 3, and all pertinent financial statements and exhibits.

This news update reflects Lixte Biotechnology’s ongoing efforts to further its collaborative research endeavors in the field of oncology treatments.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Lixte Biotechnology’s 8K filing here.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.